Description of Kyprolis (Carfilzomib)
Kyprolis is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically it is a tetrapeptide epoxyketone and an analog of epoxomicin.
Its use and Indications
Kyprolis® for injection is approved to treat patients with multiple myeloma who have received at least 2 prior therapies including bortezomib and an immunomodulatory agent and whose disease has progressed on or within 60 days of completion of the last therapy.
For treatment related information, please consult your treating Physician.
Kyprolis for injection is supplied as an individually cartooned as a single use vial containing a dose of 60 mg of carfilzomib as a white to off-white lyophilized cake or powder.
Storage and handling
Unopened vials should be stored refrigerated (2° to 8° degrees C)
How do we source the Drug?
Super Specialities Pharma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is also essential.
Company that Manufactures/ Markets:
M/s Onyx Pharmaceuticals, Inc
Mob No: +91 7738100125, +917738151650
E Mail: firstname.lastname@example.org